01—Abstract
Summary
Summary of the 8-K filed April 28, 2026. Cited figures are marked; the original filing is the authoritative source.
McKesson Corporation (MCK) announced on April 28, 2026, the execution of a new, larger revolving credit facility.
This new facility, totaling $5.0 billiona, replaces two previous credit agreements with a combined capacity of $5.0 billion. The new agreement extends the maturity date to April 2031, providing enhanced long-term financial flexibility. Crucially, the new credit facility introduces a financial covenant requiring McKesson to maintain a total debt to Consolidated EBITDA ratio of no greater than 4.25x, with a temporary step-up to 4.75x allowed following significant acquisitions.
This covenant is important for investors as it sets a clear leverage limit, though it excludes the Medical-Surgical Solutions segment. The company had no outstanding borrowings under its previous facilities at the time of this transition, indicating a proactive approach to its capital structure.
02—Key points
Key Highlights
- McKesson entered into a new $5.0 billion revolving credit facility maturing in April 2031.
- The new facility replaces previous credit lines totaling $5.0 billion ($1.0 billion 364-day and $4.0 billion five-year).
- The company had no outstanding borrowings under the terminated credit facilities.
- A new financial covenant requires a total debt to Consolidated EBITDA ratio of no greater than 4.25x.
- A temporary step-up in the leverage ratio to 4.75x is permitted after acquisitions involving at least $500 million in cash consideration.
- The Medical-Surgical Solutions segment's debt and EBITDA are excluded from the leverage covenant calculation.
- The new facility offers flexibility with a sublimit for borrowings in Canadian Dollars, British Pound Sterling, and Euros, and can be increased further.
03—Questions
Frequently Asked Questions
What is the significance of the new revolving credit facility?
The new $5.0 billion revolving credit facility provides McKesson with increased long-term financial flexibility and extends its borrowing capacity maturity to April 2031. It replaces older facilities, indicating a strategic update to the company's capital structure.
What are the key financial covenants associated with the new credit facility?
The primary financial covenant requires McKesson to maintain a total debt to Consolidated EBITDA ratio not exceeding 4.25x. This ratio can temporarily increase to 4.75x if the company completes an acquisition with at least $500 million in cash consideration. Importantly, the debt and EBITDA from the Medical-Surgical Solutions segment are excluded from this calculation.
Were there any outstanding borrowings under McKesson's previous credit facilities?
No, the filing explicitly states that there were no borrowings outstanding under the existing credit facilities at the time they were terminated. This suggests McKesson entered into the new facility with a clean slate and is managing its debt proactively.
How does the new credit facility compare in size and maturity to the old ones?
The new facility is for $5.0 billion, the same total capacity as the combined previous facilities ($1.0 billion + $4.0 billion). However, the maturity has been extended significantly, with the new facility due in April 2031, compared to the previous maturities in May 2026 and November 2029.
04—Continue